^
BIOMARKER:

Chr amplification(1)(q21)

News
Twitter
Trials
Chr amplification(1)(q21)
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials
Chr amplification(1)(q21)
Multiple Myeloma
thalidomide
Resistant: C3 – Early Trials
Chr amplification(1)(q21)
Multiple Myeloma
Isa-KRd
Sensitive: C3 – Early Trials
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + APG-2575
Sensitive: D – Preclinical